| 1. |
- Behre, Carl Johan, 1968
(författare)
-
Adiponectin, obesity and atherosclerosis.
- 2007
-
Ingår i: Scandinavian journal of clinical and laboratory investigation. - : Informa UK Limited. - 0036-5513 .- 1502-7686. ; 67:5, s. 449-58
-
Forskningsöversikt (refereegranskat)abstract
- The circulating protein adiponectin has been the subject of immense interest ever since it was first discovered in the mid-1990s. The protein is uniquely produced and secreted by mature adipocytes and is believed to have important anti-inflammatory and anti-diabetic effects; low levels have been shown to be predictive of future type 2 diabetes and cardiovascular disease. This review discusses adiponectin in relation to obesity, inflammation, insulin resistance and atherosclerosis.
|
|
| 2. |
- Birgens, Henrik, et al.
(författare)
-
The thalassaemia syndromes
- 2007
-
Ingår i: Scandinavian Journal of Clinical & Laboratory Investigation. - : Informa UK Limited. - 1502-7686 .- 0036-5513. ; 67:1, s. 41603-41603
-
Forskningsöversikt (refereegranskat)abstract
- The thalassaemia syndromes, endemic in the Mediterranean area, the Middle East, the Indian subcontinent, the Far East and in tropical Africa, are the most common hereditary disorders in humans, and millions of people are affected by diseases. Due to a widespread population flow between continents in recent past centuries, the thalassaemias are now occurring with relatively high frequency in many non-endemic areas. In the Nordic countries, homozygous thalassaemia is still relatively rare, and most health-care personnel are not familiar with these diseases. This article focuses on two important issues, namely the biological and the clinical aspects of thalassaemia.
|
|
| 3. |
- Breimer, Lars H., et al.
(författare)
-
Has folate a role in the developing nervous system after birth and not just during embryogenesis and gestation?
- 2012
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - London, United Kingdom : Informa Healthcare. - 0036-5513 .- 1502-7686. ; 72:3, s. 185-191
-
Forskningsöversikt (refereegranskat)abstract
- It is now 30 years since the first publications stating that supplementation with folate could prevent neural tube defects appeared and 20 years since the definitive data, including prevention of other birth defects. Since then epidemiological studies and animal experiments have identified folate as a molecule at the crossroads of neural development. Fortification of food has greatly reduced the incidence of spina bifida. Much interest has focussed on long-term sequelae in children born to mothers severely deprived of folate (and other nutrients) such as during the Dutch Hunger Winter of 1944 and in poor parts of the world. In addition, deficiency in folate and B12 are increasingly discussed as a possible contributing factor in dementia and congenital orofacial and heart malformations. The year 2011 saw the publication of a study that implicated low folate intake in poorer school performance of adolescents as judged by school marks. This has enormous social implications but needs confirmation from other settings. This review assesses the current state of evidence and sets the data in context of whether folate has a role in the development and plasticity of the nervous system even after birth, with particular emphasis on childhood and adolescence.
|
|
| 4. |
- Breimer, Lars H., et al.
(författare)
-
Immune checkpoint inhibitors of the PD-1/PD-L1-axis in non-small cell lung cancer : promise, controversies and ambiguities in the novel treatment paradigm
- 2020
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - : Taylor & Francis. - 0036-5513 .- 1502-7686. ; 80:5, s. 360-369
-
Forskningsöversikt (refereegranskat)abstract
- Immune checkpoint inhibitors (ICIs) have received much attention not least for melanoma since the award of the Nobel prize in 2018. Here, we review the current state of knowledge about the use of these monoclonal antibodies (mAbs) in non-small cell lung cancer (NSCLC). These drugs have generally been conditionally approved on limited early data and there are few long-term follow-up data from randomized clinical trials. The effect observed for NSCLC thus far is, on average, moderately better than that obtained with chemotherapy. Severe side-effects are more common than might have been expected. The drugs themselves are expensive and are associated with time-consuming histopathologic testing even though the predictive value of these tests can be discussed. In addition, monitoring for side-effects involves increased workload and budgetary expense for clinical chemistry laboratories. Here, we review and summarize the current knowledge, controversies and ambiguities of ICIs for the treatment of NSCLC.
|
|
| 5. |
- Christoffersen, C., et al.
(författare)
-
Apolipoprotein M: Progress in understanding its regulation and metabolic functions
- 2006
-
Ingår i: Scandinavian Journal of Clinical & Laboratory Investigation. - : Informa UK Limited. - 1502-7686 .- 0036-5513. ; 66:7, s. 631-637
-
Forskningsöversikt (refereegranskat)abstract
- ApoM is a novel apolipoprotein mainly present in high-density lipoprotein (HDL). It belongs to the lipocalin protein superfamily and may bind a small but so far unknown lipophilic ligand. It is secreted without cleavage of its hydrophobic signal peptide, which probably anchors apoM in the phospholipid moiety of plasma lipoproteins. Recent studies suggest that apoM may affect HDL metabolism and have anti-atherogenic functions. The subfraction of human HDL that contains apoM therefore protects LDL from oxidation and mediates cholesterol efflux more efficiently then HDL without apoM. In addition to hepatocytes, apoM is highly expressed in kidney proximal tubule cells. Recent data suggest that apoM is secreted into the pre-urine from the tubule cells but is normally taken up again in a megalin-dependent fashion. Further studies of mice with genetically modified apoM expression will be essential to unravel the potential roles of apoM in lipoprotein metabolism, atherosclerosis and kidney biology.
|
|
| 6. |
- Gustafsson, Dan, et al.
(författare)
-
Tissue zinc levels in a child with hypercalprotectinaemia and hyperzincaemia : a case report and a review of the literature
- 2012
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - London, United Kingdom : Informa Healthcare. - 0036-5513 .- 1502-7686. ; 72:1, s. 34-38
-
Forskningsöversikt (refereegranskat)abstract
- Background: A girl suffering from a rare syndrome of unknown aetiology, termed hypercalprotectinaemia, was evaluated for tissue zinc status, because calprotectin is a protein which chelates Zn at multiple binding-sites, which might have affected the distribution of Zn in her body.Methods: Measurement of serum, urine, hair and nail zinc (Zn) concentration, complemented with measurement of total Zn in ultrafiltrates of plasma.Results: Her serum Zn concentration was 105-133 mu mol/L. Zn levels in her hair (102 mu g/g), nail (90 mu g/g) and urine (3-12 mu mol/L; 20-80 mu g/dL) were all at the lower end of the reference intervals described in the sparse literature. Zn concentrations in ultrafiltrates of plasma were below the detection limit (<100 nmol/L). Thus, the elevated serum Zn did not translate into a similarly increased level of Zn in any of the tissues tested, nor in free Zn concentrations. Instead it appeared to be a result of Zn being chelated to binder proteins, most probably calprotectin.Conclusion: Her grossly elevated serum calprotectin concentration is probably able to raise circulating total Zn concentrations without raising ionized concentrations, but this Zn remains confined to the circulating blood as well as to excreted body fluids, particularly faeces.
|
|
| 7. |
- Hillarp, A
(författare)
-
Molecular analysis of the beta-chain of human C4b-binding protein
- 1991
-
Ingår i: Scandinavian journal of clinical and laboratory investigation. Supplementum. - : Informa UK Limited. - 0085-591X .- 0036-5513 .- 1502-7686. ; 204, s. 57-69
-
Forskningsöversikt (refereegranskat)abstract
- C4b-binding protein (C4BP) is a multimeric glycoprotein in plasma with important regulatory functions in the complement system. It occurs in two forms, as free protein and in a non-covalent bimolecular complex with the vitamin K-dependent protein S. Protein S is an important anticoagulant and enhances the rate of inactivation by activated protein C of blood coagulation factors, Va and VIIIa. Protein S bound to C4BP is inactive as an anticoagulant, indicating C4BP to have a regulatory function in the blood coagulation process. Approximately 50% of C4BP in plasma circulates in complex with protein S, but little has been known about as to how these proteins interact. This report describes the structure of C4BP and its relation to protein S binding. A novel C4BP subunit, designated the beta-chain, which in all likelihood contains the protein S binding site, has been identified, isolated and characterized. The major form of C4BP is composed of seven alpha-chains and one beta-chain, and the subunits are covalently linked by their carboxy-terminal regions giving the molecule a spider-like quaternary structure. A subpopulation of C4BP, which does not bind protein S, was found to lack the beta-chain. This provides support for the concept that the single protein S binding site is located on the beta-chain. The beta-chain is structurally related to the alpha-chain of C4BP, and both subunits belong to the superfamily of C3b/C4b-binding proteins. The genes coding for the alpha- and beta-chains of C4BP were found to be closely linked within a cluster of genes, coding for structurally related proteins, on the long arm of human chromosome 1.
|
|
| 8. |
- Modell, B., et al.
(författare)
-
Epidemiology of haemoglobin disorders in Europe : An overview
- 2007
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - : Informa UK Limited. - 0036-5513 .- 1502-7686. ; 67:1, s. 39-69
-
Forskningsöversikt (refereegranskat)abstract
- Objective. As a result of global population movements, haemoglobin disorders (thalassaemias and sickle cell disorders) are increasingly common in the formerly non-indigenous countries of Northern and Western Europe and in the indigenous countries of Southern Europe. This article presents an overview of the changing picture and a method for assessing service needs. Method. Data on country of birth or ethnic origin of residents are adjusted to obtain the estimated proportions of residents and births in non-indigenous groups at risk for haemoglobin disorders in European countries. The results are combined with prevalence data in each country of origin to obtain country prevalence estimates. Service indicators (annual tests or other interventions required to ensure equitable delivery of treatment and prevention) are then derived by country. Results. Haemoglobin disorders now occur at comparable frequency throughout Northern, Western and Southern Europe. Annually, there are more affected conceptions in Northern and Western than in Southern Europe, and sickle cell disorders are more common than thalassaemias. There is growing need for health policy-makers to support motivated professionals working to develop optimal patient care, carrier diagnosis, genetic counselling and access to prenatal diagnosis throughout the Region. Conclusion. There is a strong case for pan-European collaboration on haemoglobin disorders to share policies, standards and the instruments required to support them. These include methods for needs assessment, service standards, education and information strategies and materials, and methods for evaluating service delivery. © 2007 Taylor & Francis.
|
|
| 9. |
- Ronquist, Gunnar, et al.
(författare)
-
Inherited, non-spherocytic haemolysis due to deficiency of glucose-6-phosphate dehydrogenase
- 2007
-
Ingår i: Scandinavian Journal of Clinical and Laboratory Investigation. - : Informa UK Limited. - 0036-5513 .- 1502-7686. ; 67:1, s. 105-111
-
Forskningsöversikt (refereegranskat)abstract
- The about 400 million individuals worldwide suffering from a hereditary deficiency of the enzyme glucose-6-phosphate dehydrogenase (G6PD) may experience different degrees of haemolytic anaemia. Haemoglobin is present in very high concentrations in the erythrocyte cytoplasm, at risk of falling out of solution if the internal environment or the haemoglobin itself is changed. G6PD is a crucial enzyme producing reduced glutathione in the erythrocyte cytoplasm for the purpose of protecting haemoglobin against oxidative damage. The presence of unopposed oxidizing agents leading to oxidation of the sulfhydryl bridges between parts of the haemoglobin molecule decrease the solubility of haemoglobin, leading to precipitations called Heinz bodies. The laboratory investigation of G6PD deficiency is commonly done by a quantitative spectrophotometric analysis or by a rapid fluorescent spot test detecting the generation of NADPH from NADP. Genetic tests based on polymerase chain reaction detect specific mutations and may be used for population screening, family studies, or prenatal diagnosis.
|
|
| 10. |
- Zetterberg, Henrik, 1973
(författare)
-
Update on amyloid-beta homeostasis markers for sporadic Alzheimer's disease.
- 2009
-
Ingår i: Scandinavian journal of clinical and laboratory investigation. - : Informa UK Limited. - 1502-7686 .- 0036-5513. ; 69:1, s. 18-21
-
Forskningsöversikt (refereegranskat)abstract
- Amyloid-beta (Abeta) is either directly involved in the pathogenesis of Alzheimer's disease (AD) or tightly correlated with other primary pathogenic factors. It is produced from amyloid precursor protein (APP) by proteolytic processing dependent on the beta-site APP-cleaving enzyme 1 (BACE1) and gamma-secretase, and is degraded by a broad range of proteases. This update summarizes the currently available studies that have determined the usefulness of BACE1 and secreted fragments of APP and Abeta as cerebrospinal fluid biomarkers for AD.
|
|
